Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on molecular glue degrader (MGD)-based medicines, has announced its participation in two upcoming investor conferences. The company will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, in New York. Additionally, CEO Markus Warmuth will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 9:00 a.m. ET. The fireside chat will be available via webcast on the company's investor relations website.

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

• Morgan Stanley 23^rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.
• Stifel 2025 Virtual Immunology and Inflammation Forum – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 15, 2025, at 9:00 a.m. ET.

A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

When is Monte Rosa Therapeutics (GLUE) presenting at the Morgan Stanley Healthcare Conference 2025?

Monte Rosa Therapeutics will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025 in New York, NY.

What time is Monte Rosa's (GLUE) presentation at the Stifel 2025 Virtual Immunology Forum?

CEO Markus Warmuth will participate in a fireside chat at the Stifel Virtual Forum on September 15, 2025, at 9:00 a.m. ET.

Where can I watch Monte Rosa Therapeutics' (GLUE) Stifel conference presentation?

The fireside chat webcast will be available in the 'Events & Presentations' section of Monte Rosa's website at ir.monterosatx.com, with a replay available for 30 days.

What type of medicines is Monte Rosa Therapeutics (GLUE) developing?

Monte Rosa Therapeutics is developing novel molecular glue degrader (MGD)-based medicines as a clinical-stage biotechnology company.